Pioneering Discovery of Novel Therapeutics
VRise is a precision oncology company pursuing ground-breaking discovery and development of novel small molecules. We target pathways that determine cancer growth and proliferation using a proprietary discovery engine.
More than 30 percent of all human cancers – including 95 percent of pancreatic cancers and 45 percent of colorectal cancers — are driven by mutations of the RAS family of genes.
-NIH RAS Initiative
